Latest news and press releases about Nuvalent, Inc. (NUVL): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain.
Price
| Price | $123.96 |
| Market Cap | $9.1B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 8.30 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABVX · ARWR · AXSM · CRSP · CYTK · JAZZ · MRUS
Explore sector: Healthcare · Biotechnology
More sections of NUVL: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks